CAPOX Regimen Guidelines for Colorectal Cancer Treatment

Standard Dosing Schedule

The National Comprehensive Cancer Network recommends administering CAPOX for 8 cycles (24 weeks/6 months total duration), with each cycle repeated every 3 weeks, for adjuvant treatment of colorectal cancer 1, 2, 3
The standard CAPOX regimen consists of oxaliplatin 130 mg/m² IV infusion over 2 hours on day 1, and capecitabine 1,000 mg/m² orally twice daily on days 1-14, repeated every 3 weeks 1, 2, 4, 5, 6

High-risk stage II and low-risk stage III colon cancer patients may receive only 3 months (4 cycles) of CAPOX based on IDEA study results, as recommended by the American Society of Clinical Oncology 1, 2, 3
All other stage III patients should receive the full 6 months (8 cycles) of CAPOX, according to the National Comprehensive Cancer Network guidelines 1, 2, 3

Adjuvant chemotherapy must start within 3 weeks after postoperative recovery and no later than 2 months postoperatively, as recommended by the European Society for Medical Oncology 1, 2, 3

Discontinue oxaliplatin after 3-4 months if significant neurotoxicity (≥ grade 2) develops, but continue capecitabine to complete the full 6-month treatment duration, as suggested by the Chinese Society of Clinical Oncology 6, 7
The Chinese Society of Clinical Oncology guidelines emphasize that CAPOX is preferred over mFOLFOX6 based on IDEA study results 1, 2

For metastatic colorectal cancer, CAPOX is typically continued until disease progression or unacceptable toxicity, without a predetermined cycle limit, according to the National Comprehensive Cancer Network guidelines 4, 5, 8

Do not use CAPOX beyond 6 months in the adjuvant setting unless within a clinical trial, as recommended by the American Society of Clinical Oncology 1, 2, 3
Do not continue oxaliplatin if grade 2 or higher neurotoxicity develops; switch to capecitabine monotherapy to complete the 6-month duration, as suggested by the European Society for Medical Oncology 6, 7
North American patients may require dose reduction of capecitabine to 850 mg/m² twice daily due to increased toxicity compared to European patients, according to the National Comprehensive Cancer Network guidelines 4, 5, 8, 6

There is limited evidence for oxaliplatin benefit in patients aged ≥70 years without high-risk features, as noted by the International Society of Geriatric Oncology 7
Patients with dMMR/MSI-H Stage II disease may not benefit from fluoropyrimidine-based therapy and should be considered for alternative approaches, according to the American Society of Clinical Oncology 7

The NCCN recommends a CAPOX regimen of oxaliplatin 130 mg/m² IV over 2 hours on day 1, combined with capecitabine 850–1000 mg/m² taken orally twice daily for days 1–14, repeated every 3 weeks. 9, 10

North American patients experience greater capecitabine‑related toxicity than European patients and may require lower starting doses. 9, 10, 11
While European studies commonly used capecitabine 1000 mg/m² twice daily, the NCCN suggests initiating North American patients at 850 mg/m² twice daily. 9, 10
For patients with good performance status, a starting dose of capecitabine 1000 mg/m² twice daily can be used, provided close monitoring during the first cycle. 11
The impact of lower capecitabine doses on efficacy has not been evaluated in large‑scale randomized trials. 9, 10, 11

Oxaliplatin may be re‑introduced after temporary discontinuation for neurotoxicity, provided the discontinuation was not due to disease progression. 11

When bevacizumab is added for metastatic disease, the recommended dose is 7.5 mg/kg IV on day 1 every 3 weeks. 9, 10
Bevacizumab can be administered safely at an infusion rate of 0.5 mg/kg/min (7.5 mg/kg over 15 minutes). 9
Multiple biologic agents should not be combined in the same regimen. 11
Bevacizumab should be discontinued once disease progression occurs on a bevacizumab‑containing regimen. 11

Do not assume that the European capecitabine dose of 1000 mg/m² twice daily is appropriate for all North American patients, as toxicity profiles differ markedly. 9, 10, 11
Single‑agent capecitabine is ineffective as salvage therapy after failure of a fluoropyrimidine‑containing regimen and should be avoided. 10